Background and aims Corticosteroid is effective in alleviating immune-related adverse events (irAEs) of immune checkpoint blockade (ICB). However, prophylactic use of corticosteroid to prevent irAEs is not recommended due to a looming concern that it may attenuate anti-tumor effect of ICB. This study aims to investigate whether corticosteroid premedication may compromise anti-tumor efficacy of dual… Continue reading Corticosteroid premedication on anti-tumor effect of immune checkpoint blockade in murine hepatocellular carcinoma models
Tag: Skin Cancer
Anti-PD-1 treatment for MSI-H/MMRD tumors. A journey from genomics to transformative patient breakthroughs
André and colleagues present the final report on the impactful results of the Keynote-177 trial after 5 years of OS follow-up.1 The roots of this breakthrough that has led to the incorporation of anti-PD-1 agents into the treatment algorithm of patients with MSI-H/MMRD tumors stretch back to 1993, when Manuel Perucho and Bert Vogelstein respective… Continue reading Anti-PD-1 treatment for MSI-H/MMRD tumors. A journey from genomics to transformative patient breakthroughs
Corrigendum to “Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group”
The authors regret that in Table 8, the estimated prevalence of the BRAF V600E mutation in cholangiocarinoma should be 5%, not 50% as reported in the original publication. The corrected Table 8 is given below.
Using light to activate treatments in the right place
Acting in the right place at the right time is the key to effective medical treatment with minimal side effects. However, this feat remains difficult to achieve. Biologists and chemists have now succeeded in developing a tool that controls the location at which a molecule is activated by a simple pulse of light lasting only… Continue reading Using light to activate treatments in the right place
FDA Approves Injectable Nivolumab, an Alternative to IV Infusion
The injectable form of nivolumab, called Opdivo Qvantig, is quicker and easier to give, several oncologists said, and is just as effective as the intravenous form. Injectable forms of other immunotherapies are also on the horizon.
[Articles] Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study
Our findings suggest that ipilimumab plus nivolumab maintains efficacy to at least 7 years in patients with active asymptomatic brain metastasis. Upfront ipilimumab plus nivolumab should be the standard of care for patients with melanoma brain metastasis; a trial investigating the role of stereotactic surgery in this new paradigm is ongoing.
Targeting adenosine enhances immunotherapy in MSS colorectal cancer with EGFRvIII mutation
Background Patients with microsatellite stable (MSS) colorectal cancer (CRC) often display resistance to immunotherapy. Epidermal growth factor receptor (EGFR)-targeted therapies have shown potential in enhancing immunotherapy, yet clinical benefits remain unfulfilled, which may relate to inadequate patient stratification. Methods Circulating tumor cells and tumor tissues were collected from multicenter cohorts of patients with CRC receiving… Continue reading Targeting adenosine enhances immunotherapy in MSS colorectal cancer with EGFRvIII mutation
Acetyltransferase NAT10 inhibits T-cell immunity and promotes nasopharyngeal carcinoma progression through DDX5/HMGB1 axis
Background Immunosuppression significantly contributes to treatment failure in nasopharyngeal carcinoma (NPC). Messenger RNA (mRNA) modifications such as methylation and acetylation play crucial roles in immunosuppression. However, N4-acetylcytidine (ac4C), the only acetylation modification event has rarely been studied in NPC. Methods First, clinical tissue samples and nude mouse models were used to explore the expression of… Continue reading Acetyltransferase NAT10 inhibits T-cell immunity and promotes nasopharyngeal carcinoma progression through DDX5/HMGB1 axis
Efficacy and safety of nivolumab plus ipilimumab in patients with metastatic variant histology (non-clear cell) renal cell carcinoma
Background Nivolumab plus ipilimumab (nivo/ipi) is a standard of care first-line (1 L) therapy for patients with metastatic clear-cell renal cell carcinoma (ccRCC), but its role in patients with metastatic, non-ccRCC has not been fully defined. We report a single-institution experience with nivo/ipi in non-ccRCC. Methods Between November 2017 and February 2024, 55 patients with… Continue reading Efficacy and safety of nivolumab plus ipilimumab in patients with metastatic variant histology (non-clear cell) renal cell carcinoma
Comparison of survival outcomes for patients with Lynch vs non‐Lynch syndrome and microsatellite unstable colorectal cancer treated with immunotherapy
Abstract Background Alterations in mismatch repair (MMR) genes like MLH1, MSH2, MSH6, and PMS2 can lead to microsatellite instability–high (MSI-H) tumors. These mutations can be inherited, as in Lynch syndrome (LS), or occur de novo. Although immune checkpoint inhibitors (ICI) improves survival in MSI-H colorectal cancer (CRC) compared to chemotherapy, data comparing outcomes for patients with… Continue reading Comparison of survival outcomes for patients with Lynch vs non‐Lynch syndrome and microsatellite unstable colorectal cancer treated with immunotherapy